Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.74 |
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | DDT | P30046 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758118 | 0.90 | ELANE (0.75) | ELANECCR1KDM4ERECQLPPARA | |
| SCHEMBL5758770 | 0.89 | ELANE (0.80) | ELANECCR1KDM4ERORCRECQL | |
| SCHEMBL5757209 | 0.88 | ELANE (0.79) | ELANECCR1KDM4ERECQLNOTUM | |
| SCHEMBL5756606 | 0.88 | ELANE (0.79) | ELANECCR1KDM4ERORCRECQL | |
| SCHEMBL5755788 | 0.88 | ELANE (0.79) | ELANECCR1KDM4ENOTUMDDT | |
| SCHEMBL5756979 | 0.87 | ELANE (0.78) | ELANECCR1KDM4ERECQLNOTUM | |
| SCHEMBL5756834 | 0.87 | ELANE (0.78) | ELANECCR1NOTUM | |
| SCHEMBL5759291 | 0.87 | ELANE (0.78) | ELANECCR1KDM4ERECQLNOTUM | |
| SCHEMBL5758863 | 0.87 | ELANE (0.56) | ELANEKDM4EL3MBTL1 | |
| SCHEMBL8234626 | 0.87 | ELANE (0.71) | ELANECCR1MLYCDMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CCR1 186/4885KDM4E 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.